甲状腺腺瘤患者miR-146b的表达及与BRAF突变的相关性研究  

Expression of the thyroid adenoma miR-146b and BRAF mutation

作　　者：杨明 于春晓[2] 

机构地区：[1]山东省东营市河口区中医院普通外科,257234 [2]山东大学附属省立医院内分泌科,257234

出　　处：《中华临床医师杂志（电子版）》2013年第13期101-103,共3页Chinese Journal of Clinicians(Electronic Edition)

基　　金：国家自然科学基金(81101590)

摘　　要：目的：检测miRNA-146在甲状腺癌（ TC）组织中的表达水平，并分析其与BRAF基因突变及临床病理特征的关系。方法采用免疫组化法，对40例甲状腺癌组织、40例正常组织中miRNA-146表达水平进行检测，并根据染色程度和阳性细胞数进行综合评分；采用聚合酶链式反应（ PCR）对甲状腺癌中BRAF突变进行检测，同时分析miRNA-146表达水平与BRAF突变之间的相关性。对TC患者作1～2年的随访，以观察其生存期。结果40例TC患者中，13例患者miRNA-146呈阳性（32.5％），27例患者呈阴性（67.5％）；30例正常受试者miRNA-146呈阳性（90.0％），10例患者呈阴性（10.0％）；两组比较，差异具有统计学意义（χ2＝136.708，P＝0.000）；TC患者miRNA-146的阳性表达与TC患者的临床分期、肿瘤直径及是否发生肿瘤包膜侵犯、淋巴结转移、BRAF突变等因素密切相关（ P＜0.05）；miRNA-146阴性与阳性患者中，总体生存期未发现显著差异（ P＝0.425）。结论 miRNA-146在TC组织中呈低表达，与BRAF突变、TC的发生发展及侵袭转移关系密切。Objective To detect miRNA-146 expression levels in the tissues of thyroid cancer （ TC） ,and to analyze its relationship with the BRAF mutation and clinicopathological features .Methods The expression levels of miRNA-146 in 40 cases of thyroid cancer and 40 cases of normal tissue were detected by the immunohistochemical method.Composite scored based on the degree of staining and the number of positive cells .In order to observe the survival of patients with TC,they were followed up for 1 to 2 years.Results 40 cases of TC patients,13 patients miRNA-146 were positive（32.5%）,negative in 27 patients（67.5%）,30 normal subjects miRNA-146 were positive （90.0%）,negative in 10 patients（10.0%）.The TC patients miRNA-146 of expression and TC patients with clinical stage,tumor size and tumor capsular invasion ,lymph node metastasis ,BRAF mutation and other factors were closely related,the differences were statistically significant （P＆lt;0.05）.miRNA-146 negative and positive patients,overall survival did not find significant differences （ Logrank P=0.425 ） .Conclusion miRNA-146 expression is low in TC organization,is closely related to the BRAF mutation and the TC occurrence of development ,invasion and metastasis.

关 键 词：甲状腺肿瘤 微RNAS BRAF 突变 相关性 

分 类 号：R736.1[医药卫生—肿瘤]